📰 SLN: Silence Therapeutics Upsizes Offering to $175M, Prices at $13.50 After Phase 2 Win

News: BusinessWire

Ticker: SLN | Score: 9/10 | Sentiment: Neutral

Summary (Wiseek AI)

Silence Therapeutics priced its upsized public offering at $13.50 per ADS, successfully raising $175 million. This represents a 17% increase from the initial $150 million deal launched two days prior. The pricing reflects a 9.3% discount to the last closing price of $14.88, and the new shares are expected to dilute existing holders by approximately 24% based on the pre-offering market capitalization of $729 million. This strategic move follows blockbuster Phase 2 SANRECO data for divesiran, which caused shares to soar, allowing the company to capitalize on its momentum. The offering is anticipated to close on August 13, with Jefferies, Morgan Stanley, Cantor, and William Blair serving as joint bookrunners. While the discount and dilution are notable, the capital raise significantly strengthens the company's balance sheet in preparation for pivotal development.

Further Research: 🤖 Wiseek AI Analysis | 📰 Original Article

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.